Expected Moves

Around major fall neurology and psychiatry meetings in October 2026, Seaport Therapeutics is likely to provide an update on its CNS pipeline from a base near $16.5. Encouraging early clinical or translational data and clear differentiation could re-rate the stock toward $23.00, while inconclusive signals or delays could push shares down toward $23.00 as investors question the platform’s risk-reward.

With sustained negative free cash flow and a growing clinical program, Seaport Therapeutics is likely to explore an equity or hybrid capital raise around late 2026 from a base near $7.5. A well-timed, modestly sized raise with supportive institutions and a clear use-of-proceeds story could keep shares around $9.5, while a larger-than-expected or deeply discounted offering could pressure the stock toward $9.50.

Q3 2026 earnings in mid-November from a base near $10.5 will update investors on cash burn, trial milestones, and 2027 planning. Confirmation that Seaport Therapeutics can sustain key CNS programs without near-term dilution could support a recovery toward $14.00, while higher-than-expected burn or deferral of pivotal studies could push the stock toward $14.00.